Alembic Pharmaceuticals Limited announced it has received final approval from the US Food and Drug Administration for psoriasis drug Acitretin in 10 mg, 17.5 mg, and 25 mg strengths. Alembic Pharmaceuticals Limited shares were trading at ₹1,218.65, up by 32 points (2.7 per cent) on NSE and ₹1,218.95, up by 34.50 points (2.91 per cent) on BSE at around 3 pm. Acitretin is a retinoid medication related to vitamin A that is used to treat severe psoriasis in adults. This approval marks Alembic’s 212th ANDA approval from the USFDA, including 184 final approvals and 28 tentative approvals. The estimated market size for Acitretin capsules was $21 million for the 12 months ending June 2024, according to IQVIA data.

Source: The Hindu August 07, 2024 15:29 UTC